On Friday, November
02, 2012, Genetic
Technologies (plaintiff) recorded a suit against PreventionGenetics
(defendant) for patent infringement in the U.S. District Court of Wisconsin
(case no. 3:12-cv-00792).
Genetic Technologies,
an Australian company focuses primarily on the testing and evaluation of
forensic evidence as it relates to human identification. PreventionGenetics
provides clinical DNA testing and banking and genomics services for the medical
and research.
The patent US5612179
involved in this suit is currently assigned[1]
to Genetic Technologies (Source: MaxVal’s
Assignment Database). The patent entitled Intron Sequence Analysis Method for
Detection of Adjacent and Remote Locus Alleles as Haplotypes was issued on
March 18, 1997 and expires[2] on
March 18, 2014. The patent '179 generally relates to methods of analysis of
non-coding DNA sequences.
According to
the complaint, the defendant provides clinical DNA testing services including CF,
Fragile-X, and Factor II Prothrombin. Cystic Fibrosis (CF) is one of the most
common single gene disorders and is caused by mutations in the cystic fibrosis
transmembrane conductance regulator ("CFTR")
gene. Defendant’s analysis of the poly T variation at intron 8 of the CFTR gene allegedly infringes the ‘179 patent.
The plaintiff
has filed suit against the companies listed below:
Company
|
Case No.
|
Date Filed
|
Status
|
10/11/2012
|
Pending
|
||
09/26/2012
|
Pending
|
||
09/26/2012
|
Pending
|
||
09/13/2012
|
Pending
|
||
08/27/2012
|
Pending
|
||
03/30/2012
|
Pending
|
||
03/29/2012
|
Pending
|
||
03/29/2012
|
Pending
|
||
03/29/2012
|
Pending
|
||
03/29/2012
|
Pending
|
||
03/26/2012
|
Pending
|
||
01/19/2011
|
Pending
|
||
02/11/2010
|
Pending
|
The following
are the suits that are closed: Geneseek (8:12-cv-00120 and 1:12-cv-00795), Agilent Technologies (1:12-cv-00788 and 1:11-cv-01389), GlaxoSmithKline (1:12-cv-00796), Pfizer (1:12-cv-00791), Bristol-Myers Squibb (1:12-cv-00790), Merial (1:12-cv-00792), 454 Life Sciences (1:12-cv-00739), Applera (4:03-cv-01316 and 3:2003cv01316) and Covance (3:03-cv-01315).
For more details, visit MaxVal-IP and subscribe to our Litigation Alerts.
[1]Maxval
offers Patent Assignment Alert service where subscribers receive email alerts
when assignments relating to target applications, patents or entities of
interest are recorded.
[2]Expected expiration date. Patent Term Estimator is a free web-based tool that automatically
calculates patent terms and expiration dates for U.S. utility patents.
No comments:
Post a Comment